Cell Point IPO Witnesses Strong Subscription on Day 1, GMP Jump 12%

Cell Point India's initial public offering (IPO) got off to an impressive start as it garnered a subscription of 1.09 times on the first day of bidding. The IPO received strong interest from both non-institutional investors, with a subscription of 1.30 times, and retail investors, with a subscription of 0.86 times. This indicates a positive response from the market, reflecting investor confidence in the company

In addition, the grey market premium (GMP) for Cell Point IPO surged to ₹12, marking a listing premium of 12% over the issue price. The rising GMP indicates robust demand for the IPO and suggests the potential for significant listing gains.

Many Renowned Analysts, rated Cell Point IPO as a "Subscribe for Long-term and Listing Gain" opportunity, emphasising the growth prospects and potential returns for investors.

Cell Point India, a leading smartphone and electronics retail company, has garnered attention for its strong financial performance, strategic partnerships, and wide range of products. With the IPO gaining traction, investors are eagerly anticipating the listing day, expecting favorable market reception and the possibility of attractive returns.

Investors are advised to conduct thorough research and seek guidance from financial advisors before making investment decisions. The Cell Point IPO presents an opportunity for long-term investors looking to capitalize on the company's growth potential and the positive market sentiment surrounding the offering.

Cell Point is offering 5,034,000 shares at a fixed price of Rs. 100 per equity share in order to generate funds for expansion and take advantage of potential future growth. The entire amount raised in the IPO is Rs. 50.34 crores. The initial public offering's subscription period will be open until June 20, 2023. Registrar for the IPO is Bigshare Services Pvt Ltd and the shares are going to be listed on NSE SME. On Friday, June 23, 2023, the basis for share allotment will be finalised.